NewAmsterdam reports data from Phase 3 BROADWAY trial, met primary endpoint

NewAmsterdam Pharma (NAMS) announced positive topline data from the Company’s Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with established atherosclerotic cardiovascular disease, ASCVD, and/or heterozygous familial hypercholesterolemia, HeFH, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The primary endpoint was the least-squares mean of the percent change in LDL-C from baseline to day 84 for obicetrapib 10 mg compared to placebo, using imputation for missing data. The primary endpoint was achieved with statistical significance with an LDL-C reduction of 33%